General discussion, page-4936

Spot on Mickey. I am honestly betting on $1B AUD MC in a very short time-frame after the US Dual Listing and promotion by Eddie.

I'd suggest people re-read these again if they feel their conviction wavering.
https://www.reddit.com/r/ASX_Bets/comments/llr1ao/sugar_spice_and_everything_nyse_asxihl_update_2021/
https://tradingformillions.com/were-back-folks-why-incannex-healthcare-is-growing-into-the-next-billion-dollar-behemoth/

Going to re-post a section of my post, basically re-iterating what is happening here. Even before reaching the level of GW Pharma... IHL presents a compelling opportunity purely based on the value that can be unlocked on a NASDAQ Dual Listing even at the current stage we are at.

I: Compass Pathways (NASDAQ:CMPS)

Compass Pathways is currently valued at $1.8B USD, and had highs of over $2B USD. Which would be $2.3B AUD. They are currently conducting a Phase 2B Clinical Trial using psilocybin therapy for depression across 21 sites in 10 different countries.

Compass has over 10 bagged since IPOing in September 2020.

https://ir.compasspathways.com/static-files/542bb3a1-c0e6-4f1b-87fa-5fd4f2fb7a6d

In relation, IHL has planned Australia's largest ever clinical trial of psilocybin therapy for anxiety in collaboration with Monash University. This would be a Phase 2 trial and whilst a ways off from recruiting and commencing, the similarities to Compass are obvious.

II: MindMed (MMEDF:OTCQB)

MindMed boasts a valuation of $900M USD, and had highs of $1.27B USD. This would be $1.16B AUD. The company is engaging in LSD assisted therapy for anxiety, and is currently in Phase 2A of clinical development. Furthermore, they have successfully completed a Pre-IND meeting with the FDA for this project.

https://mindmed.co/news/press-release/mindmed-announces-successful-completion-of-pre-ind-meeting-with-the-fda-for-project-lucy/

IHL is engaging in a similar task with its psilocybin assisted therapy for anxiety, and will certainly seek out the FDA for a Pre-IND meeting just like MindMed when the time is right. IHL is actually about to meet with the FDA along with their consultants Camargo for a Pre-IND meeting regarding their drug IHL-675A for ARDS. A successful meeting with the FDA here would be immensely valuable to the future.

III: Cara Therapeutics (NASDAQ:CARA)

CARA is a clinical stage cannabinoid biotech company, which boasts a valuation of $1B USD. This would be $1.28B AUD. They have multiple clinical assets being developed, some in phase 2 and others in phase 3 human trials including post-surgery pain, itchiness and chronic kidney disease.

IHL is similar in that they are targeting markets such as ARDS, Obstructive Sleep Apnea, Traumatic Brain Injury and Asthma with TAM over $1B each. The former three have no existing pharmacotherapy and therefore no drug related competition. This cannot be said for CARA. However, CARA is significantly more advanced being in Phase 2 and 3 human trials whilst IHL has completed the preclinical stages for ARDS and TBI, and is looking to progress to human trials. For OSA, IHL is currently recruiting for a Phase 2B human trial and looks to commence that imminently.

Even before commercialization possibilities, IHL is arguably an amalgamation of Cara Therapeutics, Compass Pathways and MindMed. All three boast roughly $1B USD market capitalizations. What does that make IHL theoretically worth?